Philips recalls ventilators due to health risks



© Reuters. FILE PHOTO: Logo of Dutch technology company Philips is seen at its company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier/File Photo

By Toby Sterling

AMSTERDAM (Reuters) -Dutch medical equipment company Philips has recalled some breathing devices and ventilators because of a foam part that might degrade and become toxic, potentially causing cancer, it said on Monday.

Foam used to dampen the machines’ sound can when it degrades turn into small, inhaled particles, irritating airways, the group said as it announced the recall. Gases released by the degrading foam may also be toxic or carry cancer risks.

Philips Chief Executive Frans van Houten said between three and four million sleep apnea machines and ventilators would be targeted.

The group took a second 250 million euro ($303 million) charge for the issue after announcing an identical provision in its first quarter-earnings report in April, bringing the total cost of the problem to 500 million euros to date.

Shares in the group were down 4.2% to 44.43 euros by 0757 GMT in Amsterdam.

“We’re going to put all our capacity to focus entirely on replacing and repairing these units,” Van Houten said in a call. He said the process would likely take a year.

That “has a consequence that we will not be able to serve new customers, so there’s going to be a shortage in the field”.

The company’s guidance is for users of so-called CPAP machines, which help people with sleep apnea, to halt usage. Around two-thirds of Philips CPAP machines are sold in the United States.

See also  Hong Kong leader says expects city to record negative growth in 2019

Doctors with patients using life-sustaining ventilators should first consider whether the potential danger from the foam outweighs other risks, the company said.

Philips said that though the matter would cause “revenue headwinds” in the division making the devices, that would be compensated by strength in other businesses.

It left its full-year financial guidance of “low-to-mid-single-digit” comparable sales growth unchanged.

Philips spokesman Steve Klink said the company was working with health authorities on a safe replacement for the foam, but must first clear testing and regulatory hurdles.

In April Philips said first-quarter core earnings surged 74% to 362 million euros compared with the same period a year earlier, on a 9% rise in comparable sales.

($1 = 0.8263 euros)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

See also  Pandora Soars as New CEO Tells Market Strategy Shift Is Working





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here